
Opinion|Videos|April 23, 2024
Addressing the Caregiver Burden in Hepatic Encephalopathy Management
Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, highlight the importance of adhering to evidence-based guidelines and utilizing approved medications in the management of hepatic encephalopathy, emphasizing their crucial role in preventing patient relapse within 30 days of hospital discharge.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Examining the Safety Profiles of SG and Pembrolizumab in ASCENT-04
2
FDA Accepts Furosemide Autoinjector sNDA for Treatment of Edema in Chronic Kidney Disease or Chronic Heart Failure
3
FDA Approves Pirtobrutinib for Relapsed or Refractory Chronic Lymphocytic Leukemia
4
A Closer Look at Interdisciplinary Care with Unit-Based Pharmacy
5
















































































































































































































